Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209195 · ClinicalTrials.gov registry record · Phase 1
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
A Phase 1 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT01209195 is a Phase 1 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT01209195, a Phase 1 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
Interventions
- DRUG Paclitaxel
- DRUG MM-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209195
The ClinicalTrials.gov registry entry for NCT01209195 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01209195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01209195 about?
NCT01209195 is a clinical study titled "A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers". This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
What is the current status of trial NCT01209195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2010-10. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01209195?
The interventions under investigation include: Paclitaxel (DRUG), MM-121 (DRUG).
Who is sponsoring clinical trial NCT01209195?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.